Loading...
India's plasma imports from ROMANIA total $436 across 16 shipments from 2 foreign suppliers. CLINICAL CENTER OF 3 S PHARMACOLOGICAL CONSULTATIO leads with $293 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include WATSON PHARMA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for plasma — a concentrated sourcing relationship with select suppliers from ROMANIA.
CLINICAL CENTER OF 3 S PHARMACOLOGICAL CONSULTATIO is the leading Plasma supplier from ROMANIA to India, with import value of $293 across 6 shipments. The top 5 suppliers — CLINICAL CENTER OF 3 S PHARMACOLOGICAL CONSULTATIO, TERAPIA S.A — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | CLINICAL CENTER OF 3 S PHARMACOLOGICAL CONSULTATIO | $293 | 6 | 67.1% |
| 2 | TERAPIA S.A | $143 | 10 | 32.9% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | WATSON PHARMA PRIVATE LIMITED | $293 | 6 | 67.1% |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $143 | 10 | 32.9% |
ROMANIA → India trade corridor intelligence
The Romania to India trade corridor for pharmaceutical imports is currently stable. Major ports in India, including Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra, are operating without significant congestion. Freight rates have remained consistent over the past year, and the exchange rate between the Indian Rupee (INR) and the Romanian Leu (RON) is favorable for importers. No major shipping disruptions have been reported in 2025–2026.
India's Production-Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. While the scheme primarily targets domestic production, it may indirectly affect imports of finished pharmaceutical formulations containing plasma by encouraging local production of similar products. Import substitution policies are being considered to enhance self-reliance in the pharmaceutical sector.
India and Romania maintain a cordial trade relationship, with ongoing discussions to enhance pharmaceutical trade. There are no existing Free Trade Agreements (FTAs) between the two countries. Efforts are being made to recognize Good Manufacturing Practices (GMP) mutually and facilitate smoother trade processes. These initiatives aim to strengthen bilateral trade and ensure the quality of pharmaceutical imports.
The landed cost for importing finished pharmaceutical formulations containing plasma from Romania to India includes the following components:
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing plasma into India, manufacturers must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The registration process involves submitting an application to the Drugs Controller General of India (DCGI), accompanied by a fee of $1,000 USD per drug. The application must include a Certificate of Pharmaceutical Product (COPP), Good Manufacturing Practice (GMP) certificate, and a Drug Master File (DMF). The registration certificate is valid for three years. The import license, issued after registration, is also valid for three years. The entire process typically takes up to nine months.
Imported pharmaceutical formulations containing plasma must undergo quality testing at CDSCO-approved laboratories. Three consecutive batches are required for testing, with samples provided for reanalysis. The testing includes analysis methods, Certificates of Analysis (CoA) from the exporting country, impurity standards, marker compounds, and reference standards. The applicant bears the cost of testing, which is paid directly to the laboratory. Port inspections by customs drug inspectors are conducted to ensure compliance with Indian standards.
In April 2025, the Indian government mandated that all imported drugs, including finished formulations containing plasma, require both an Import Registration Certificate and an Import License from CDSCO. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy emphasizes compliance with the Drugs and Cosmetics Act and associated rules.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished pharmaceutical formulations containing plasma to meet the demand for specialized treatments not available domestically. These imports include patented or branded formulations and specific dosage forms that domestic manufacturers do not produce. The market size for such imports is significant, with a total value of $2.8 million across 215 exporters to 90 countries. The demand for plasma formulations in India is growing, driven by the need for advanced medical therapies.
The import duty structure for finished pharmaceutical formulations containing plasma (HS Code 30029010) includes a Basic Customs Duty of 10%, an Education Cess of 2%, and a Secondary Higher Education Cess of 1%, totaling 10.3%. The Integrated Goods and Services Tax (IGST) is 0%. There are no additional duties such as Anti-Dumping Duty or National Calamity Contingent Duty (NCCD) applicable to these imports. Exemption notifications are not available for imports from Romania.
Romania supplies finished pharmaceutical formulations containing plasma to India, offering competitive advantages such as patented formulations, specialized dosage forms, and adherence to quality standards. Romanian manufacturers like Clinical Center of 3 S Pharmacological Consultatio and Terapia S.A. have established a presence in the Indian market. Other suppliers include China, Germany, and the United States, with Romania holding a share of approximately 15% in this segment.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished pharmaceutical formulations containing plasma from Romania due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Romanian manufacturers offer products that complement India's domestic offerings, fulfilling specific medical needs not addressed locally.
Compared to other sources like China, Germany, and the United States, Romania offers competitive pricing, adherence to quality standards, and a favorable regulatory environment. Romanian suppliers are known for their reliability and compliance with international norms, providing a unique advantage in the Indian market.
Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency trends, stay updated on regulatory developments, conduct thorough quality assessments, and establish contingency plans for logistics.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Plasma suppliers from ROMANIA to India include CLINICAL CENTER OF 3 S PHARMACOLOGICAL CONSULTATIO, TERAPIA S.A. The leading supplier is CLINICAL CENTER OF 3 S PHARMACOLOGICAL CONSULTATIO with import value of $293 USD across 6 shipments. India imported Plasma worth $436 USD from ROMANIA in total across 16 shipments.
India imported Plasma worth $436 USD from ROMANIA across 16 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Plasma sourced from ROMANIA include WATSON PHARMA PRIVATE LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED. The largest buyer is WATSON PHARMA PRIVATE LIMITED with $293 in imports across 6 shipments.
The total value of Plasma imports from ROMANIA to India is $436 USD, across 16 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
16 Verified Shipments
2 suppliers, 2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists